Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | BCHE | P06276 | 2/20 | 0.54 |
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | PREP | P48147 | 1/20 | 0.46 |
| ▸ | FAP | Q12884 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27406245 | 0.83 | ACKR3 (0.53) | KMT2ABCHEACHEKDM4E | |
| SCHEMBL4157854 | 0.82 | ACHE (0.68) | KMT2ABCHEACHEKDM4EALDH1A1 | |
| SCHEMBL7493236 | 0.80 | KMT2A (0.69) | KMT2ABCHEACHEKDM4EALDH1A1 | |
| SCHEMBL28946798 | 0.80 | KMT2A (0.69) | KMT2ABCHEACHEKDM4EALDH1A1 | |
| SCHEMBL2443481 | 0.79 | KMT2A (0.68) | KMT2ABCHEACHEKDM4EALDH1A1 | |
| SCHEMBL13912376 | 0.79 | KMT2A (0.68) | KMT2ABCHEACHEKDM4EALDH1A1 | |
| SCHEMBL22982640 | 0.78 | TDP1 (0.50) | BCHEALDH1A1LMNAMAPT | |
| SCHEMBL22982883 | 0.78 | TDP1 (0.50) | BCHEALDH1A1LMNAMAPT | |
| SCHEMBL13814798 | 0.77 | BCHE (0.67) | KMT2ABCHEACHEKDM4EALDH1A1 | |
| SCHEMBL31324479 | 0.77 | TACR3 (0.62) | KMT2AALDH1A1GAALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143429-A1 | Quinoline Derivatives as Neurokinin Receptor Antagonists | CRAWFORTH JAMES MICHAEL | 2009-06-04 | — | — | US | disclosed |
| EP-1912967-A1 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007012900-A1 | QUINOLINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143429-A1 | Quinoline Derivatives as Neurokinin Receptor Antagonists | TACR2, TACR1, TACR3 | KMT2A 513/4885BCHE 2227/4885ACHE 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.